Cimica et al. BMC Cancer 2010, 10:634 http://www.biomedcentral.com/1471-2407/10/634 39. Isakoff MS, Sansam CG, Tamayo P, Subramanian A, Evans JA, Fillmore CM, Wang X, Biegel JA, Pomeroy SL, Mesirov JP, et al: Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc Natl Acad Sci USA 2005, 102(49):17745-17750. 40. Afshar G, Jelluma N, Yang X, Basila D, Arvold ND, Karlsson A, Yount GL, Dansen TB, Koller E, Haas-Kogan DA: Radiation-induced caspase-8 mediates p53-independent apoptosis in glioma cells. Cancer Res 2006, 66(8):4223-4232. 41. Chaturvedi V, Sitailo LA, Qin JZ, Bodner B, Denning MF, Curry J, Zhang W, Brash D, Nickoloff BJ: Knockdown of p53 levels in human keratinocytes accelerates Mcl-1 and Bcl-x(L) reduction thereby enhancing UV-light induced apoptosis. Oncogene 2005, 24(34):5299-5312. 42. Rosson GB, Vincent TS, Oswald BW, Wright CF: Drug resistance in malignant rhabdoid tumor cell lines. Cancer Chemother Pharmacol 2002, 49(2):142-148. 43. Nocentini S: Apoptotic response of malignant rhabdoid tumor cells. Cancer Cell Int 2003, 15:11. 44. Rosson GB, Hazen-Martin DJ, Biegel JA, Willingham MC, Garvin AJ, Oswald BW, Wainwright L, Brownlee NA, Wright CF: Establishment and molecular characterization of five cell lines derived from renal and extrarenal malignant rhabdoid tumors. Mod Pathol 1998, 11(12):1228-1237. 45. Kaiserling E, Ruck P, Handgretinger R, Leipoldt M, Hipfel R: Immunohistochemical and cytogenetic findings in malignant rhabdoid tumor. Gen Diagn Pathol 1996, 141(5-6):327-337. 46. Kinoshita Y, Tamiya S, Oda Y, Mimori K, Inoue H, Ohta S, Tajiri T, Suita S, Tsuneyoshi M: Establishment and characterization of malignant rhabdoid tumor of the kidney. Oncol Rep 2001, 8(1):43-48. 47. Janicke RU, Sohn D, Schulze-Osthoff K: The dark side of a tumor suppressor: anti-apoptotic p53. Cell Death Differ 2008, 15(6):959-976. 48. Ambrosini G, Seelman SL, Qin LX, Schwartz GK: The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner. Cancer Res 2008, 68(7):2312-2320. 49. Gojo I, Zhang B, Fenton RG: The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 2002, 8(11):3527-3538. 50. Hussain SR, Lucas DM, Johnson AJ, Lin TS, Bakaletz AP, Dang VX, Viatchenko-Karpinski S, Ruppert AS, Byrd JC, Kuppusamy P, et al: Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. Blood 2008, 111(6):3190-3199. 51. Pollack IF, DaRosso RC, Robertson PL, Jakacki RL, Mirro JR Jr, Blatt J, Nicholson S, Packer RJ, Allen JC, Cisneros A, et al: A phase I study of high- dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clin Cancer Res 1997, 3(7):1109-1115. 52. Zeisig R, Teppke AD, Behrens D, Fichtner I: Liposomal 4-hydroxy- tamoxifen: effect on cellular uptake and resulting cytotoxicity in drug resistant breast cancer cells in vitro. Breast Cancer Res Treat 2004, 87(3):245-254. Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/10/634/prepub doi:10.1186/1471-2407-10-634 Cite this article as: Cimica et al.: Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen. BMC Cancer 2010 10:634. Page 13 of 13 Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color ﬁgure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit